Zymeworks
ZYME · Nasdaq · United States
Share price · ZYME
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when ZYME's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 12 Nov 2026-8.9%
Nothing announced by ZYME that day or the session before.
- 11 Nov 2026-7.6%
Nothing announced by ZYME that day or the session before.
- 26 Aug 2026+6.7%
- 25 Aug 2026-4.5%
- 21 Aug 2026+7.9%
Nothing announced by ZYME that day or the session before.
- 13 Aug 2026+3.3%
Nothing announced by ZYME that day or the session before.
- 30 Jun 2026+8.5%
- 8 May 2026-10.2%
- 12 Mar 2026-7.6%
Nothing announced by ZYME that day or the session before.
- 10 Mar 2026+5.0%
Nothing announced by ZYME that day or the session before.
Share of unusual movement by asset
For each asset, the share of ZYME's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
Revefenacin(Yupelri) | Approved | Muscarinic receptors (antagonist)Small molecule | Chronic Obstructive Pulmonary Disease |
| Approved | HER2Multispecific antibody | Non-Small Cell Lung CancerBiliary Tract CancerBreast CancerGastric Cancer HER2-Positive Breast Cancer |
Discontinued programmes (1)
Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
What to watch
2027 (1)
December 2027 (1)
What to watch
Regulatory and conference events
(9)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $256M | $36M | $100M+ $0 short-term inv. | —-$24M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $4.6M | $27M | $179M+ $91M short-term inv. | $45M-$32M operating cash flow | report ↗ |
| 2026-Q1 | $2.4M | $34M | $244M+ $120M short-term inv. | $44M-$46M operating cash flow | report ↗ |
| 2025-Q3 | $28M | $36M | $65M+ $187M short-term inv. | $20M-$31M operating cash flow | report ↗ |
| 2025-Q2 | $49M | $34M | $98M+ $183M short-term inv. | —$12M operating cash flow | report ↗ |
| 2025-Q1 | $27M | $36M | $76M+ $189M short-term inv. | $23M-$3.4M operating cash flow | report ↗ |
| 2024-Q3 | $16M | $36M | $122M+ $175M short-term inv. | $30M-$5.9M operating cash flow | report ↗ |
| 2024-Q2 | $19M | $29M | $71M+ $259M short-term inv. | $38M-$25M operating cash flow | report ↗ |
| 2024-Q1 | $10M | $32M | $115M+ $230M short-term inv. | $32M-$38M operating cash flow | report ↗ |
| 2023-Q3 | $17M | $33M | $94M+ $201M short-term inv. | $29M-$43M operating cash flow | report ↗ |
| 2023-Q2 | $7.0M | $39M | $142M+ $198M short-term inv. | $51M-$6.4M operating cash flow | report ↗ |
| 2023-Q1 | $36M | — | $182M+ $159M short-term inv. | $24M-$83M operating cash flow | report ↗ |
| 2022-Q3 | $2.6M | — | $96M+ $70M short-term inv. | $48M-$73M operating cash flow | report ↗ |
| 2022-Q2 | $5.4M | — | $199M | $65M-$55M operating cash flow | report ↗ |
| 2022-Q1 | $1.9M | — | $276M | $73M-$55M operating cash flow | report ↗ |
| 2021-Q3 | $4.4M | — | $253M | $61M | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $106M | $137M | $41M+ $188M short-term inv. | $20M-$33M operating cash flow | report ↗ |
Zymeworks reported revenue of $105.97M for fiscal 2025, up 38.9% YoY from $76.3M, and R&D spend of $137M, up 1.8% YoY from $134.62M. Cash and equivalents were $41.16M, with a net loss of $81.13M (quarterly net burn of $81.13M).
The company guided to approximately $300.0M in aggregate adjusted gross operating expenditures (non-GAAP) over 2026–2028, with 2026 adjusted gross operating expenses expected about 20% lower than 2025’s $170.5M. Pipeline and partnered highlights include ongoing Phase 1 studies for ZW191 and ZW251, IND submissions for ZW209 and ZW1528 in 2026, Jazz’s planned completion of the Ziihera sBLA in first-line HER2+ gastroesophageal adenocarcinoma in 1Q 2026 with potential launch in 2H 2026, pasritamig data presented at ASCO-GU by Johnson & Johnson, and a $250.0M royalty-backed note financing from Royalty Pharma alongside $62.5M utilized for share repurchases under the $125.0M buyback program.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $76M | $135M | $66M+ $160M short-term inv. | $31M-$110M operating cash flow | report ↗ |
| 2023-FY | $76M | $144M | $158M+ $217M short-term inv. | $30M-$118M operating cash flow | report ↗ |
| 2022-FY | $412M | $209M | $401M+ $91M short-term inv. | —$144M operating cash flow | report ↗ |
| 2021-FY | $27M | — | $202M+ $51M short-term inv. | $53M-$192M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 15 sales ($6.4M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-18 | Platshon Scott · EVP, Chief Business Officer | Option exercise | 37,037 | — | — | Form 4 |
| 2026-11-18 | Platshon Scott · EVP, Chief Business Officer | Open-market sale | 15,292 | $24.95 | $382K | Form 4 |
| 2026-11-18 | Platshon Scott · EVP, Chief Business Officer | Option exercise (derivative) | 37,037 | — | — | Form 4 |
| 2026-11-13 | Moore Paul Andrew · Chief Scientific Officer | Option exercise | 25,000 | $5.82 | $146K | Form 4 |
| 2026-11-13 | Moore Paul Andrew · Chief Scientific Officer | Open-market sale | 7,367 | $26.14 | $193K | Form 4 |
| 2026-11-13 | Moore Paul Andrew · Chief Scientific Officer | Open-market sale | 7,374 | $26.09 | $192K | Form 4 |
| 2026-11-13 | Moore Paul Andrew · Chief Scientific Officer | Open-market sale | 25,000 | $26.04 | $651K | Form 4 |
| 2026-11-13 | Moore Paul Andrew · Chief Scientific Officer | Option exercise (derivative) | 25,000 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 211 reporting institutions held 70.3M shares ($1.8B, 101.8% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | EcoR1 Capital, LLC | 22,970,388 | $575.2M |
| 2 | Rubric Capital Management LP | 7,000,000 | $175.3M |
| 3 | BlackRock, Inc. | 4,553,888 | $114.0M |
| 4 | BVF INC/IL | 3,734,142 | $93.5M |
| 5 | PERCEPTIVE ADVISORS LLC | 3,510,078 | $87.9M |
| 6 | MORGAN STANLEY | 2,480,568 | $62.1M |
| 7 | BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 1,908,039 | $47.8M |
| 8 | VANGUARD CAPITAL MANAGEMENT LLC | 1,705,580 | $42.7M |
| 9 | CITADEL ADVISORS LLC | 1,150,018 | $28.8M |
| 10 | DIMENSIONAL FUND ADVISORS LP | 1,139,135 | $28.5M |
| 11 | Nextech Invest, Ltd. | 1,113,946 | $27.9M |
| 12 | STATE STREET CORP | 1,011,777 | $25.3M |
| 13 | Capricorn Fund Managers Ltd | 1,007,210 | $25.2M |
| 14 | DEUTSCHE BANK AG\ | 921,250 | $23.1M |
| 15 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 743,898 | $18.6M |